Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007

Janux Therapeutics, Inc.

Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.
Cash and short-term investments $354.3M (Dec 31, 2021: $375.0M).
FDA cleared IND for JANX007 (PSMA-TRACTr) for mCRPC; Phase 1 trial expected 2H 2022.
IND submission for JANX008 (EGFR-TRACTr) on track for 2H 2022; TROP2-TRACTr IND planned for 2023.
First TRACIr candidate (PD-L1xCD28) IND-enabling studies ongoing; IND submission expected 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.